Modern Prospection for Hepatic Arterial Infusion Chemotherapy in Malignancies with Liver Metastases

Table 1

Selective studies of combining HAIC with systemic chemotherapy for colorectal cancer.

Authors	Year	Setting	Treatment	Line	Inclusion; population	Patient no.; (treat^a)	Median OS (months)	RR	Note
Yamaguchi et al.; [26]	2011	Pro,; phase I/II	HAIC → 5-FU; IV → CPT-11 + LV; Oral tegafur/uracil	First line	Unresectable hepatic mets	Phase 1: 12 (12); Phase 2: 22 (22)	Not reach	86.4%	RCR: 63.6%
Mancini et al.; [27]	2003	Pro, Ran	Arm1: HAIC → continuous cisplatin; IV → 5-FU; Arm2: HAIC → bolus cisplatin; IV → 5-FU	First line	Unresectable hepatic mets	58 (58); 65 (65)	18	52%
Goéré et al. [28]	2010	Ret	HAIC → oxaliplatin; IV → 5-FU + LV	First line: 18; Second line: 69	Unresectable hepatic mets	87 (87)	NM	55%	5-year; survival: 56%
Gallagher et al.; [29]	2007	Ret	HAIC → FUDR + Dexa; IV → CPT-11	Failed oxaliplatin	Unresectable hepatic mets	39 (39)	18	44%
Pilati et al.; [30]	2009	Ret	Arm1: HAIC → FUDR + LV; Arm2: HAIC → FUDR + LV; IV → 5-FU + LV	NM	Unresectable hepatic mets	72 (72); 81 (81)	18; 19.1	52.7%; 50.6%

Selected studies that enroll patients with colorectal cancer to receive systemic chemotherapy in combination with HAIC are listed here. Studies designed for patients with colorectal cancer-related liver-confined metastatic disease were listed in Table 2.
∗With statistical significance.
^aActual patients’ number who received treatment.
Abbreviations—OS: overall survival, RR: response rate, Pro: prospective, Ran: randomized, Ret: retrospective, NM: not mentioned, HAIC: hepatic artery infusion chemotherapy, IV: intravenous, FUDR: floxuridine, LV: leucovorin, Dexa: dexamethasone, CPT-11: irinotecan, Mets: metastasis, and RCR: resectability conversion rate.